(Q45713235)

15 December 2017

title

Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension (English)

1 reference

15 December 2017

9

Mario Rizzetto

1 reference

15 December 2017

author name string

Wilma Debernardi-Venon

1

1 reference

15 December 2017

Claudio Barletti

2

1 reference

15 December 2017

Carlo Alessandria

3

1 reference

15 December 2017

Alfredo Marzano

4

1 reference

15 December 2017

M Baronio

5

1 reference

15 December 2017

Luca Todros

6

1 reference

15 December 2017

Giorgio Saracco

7

1 reference

15 December 2017

Alessandro Repici

8

1 reference

15 December 2017

publication date

1 February 2002

1 reference

Digestive Diseases and Sciences

15 December 2017

published in

1 reference

15 December 2017

volume

47

1 reference

15 December 2017

issue

2

1 reference

15 December 2017

page(s)

401-404

1 reference

The long-term morbidity and mortality rate in a cohort of patients with liver cirrhosis and oesophageal varices.

15 December 2017

cites work

1 reference

12 December 2020

Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites.

1 reference

12 December 2020

Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis

1 reference

12 December 2020

Portal pressure, renal function and hormonal profile after acute and chronic captopril treatment in cirrhosis

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis

1 reference

12 December 2020

Portal pressure, presence of gastroesophageal varices and variceal bleeding

1 reference

12 December 2020

Are there differences among angiotensin receptor blockers?

1 reference

12 December 2020

Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study

1 reference

12 December 2020

Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage

1 reference

12 December 2020

Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis.

1 reference

12 December 2020

Hemodynamic evaluation of the patient with portal hypertension.

1 reference

12 December 2020

Effect of chronic treatment with nadolol plus isosorbide mononitrate on liver blood flow and liver metabolic activity in cirrhosis

1 reference

12 December 2020

Wedged and free hepatic venous pressure measured with a balloon catheter

1 reference

12 December 2020

Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects

1 reference

12 December 2020

Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis

1 reference

12 December 2020

The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1013790610327

1 reference

Dimensions Publication ID

15 December 2017

1047332425

0 references

1 reference